PATIENT INFORMATION														
First name			I	MI Last nar	ne				Date of	birth (MM/DD/YYY	Y)			
Biological sex	MRN (medical record numb	er)		Ancestry										
O Male O Female					' _	can American 🛛 White/ French Canadian 🔵 Sepł		Ashkenaz	,	O Hispanic O Other:	Native American			
-	(for billing contact and repor	t access afte	r clinician re			• • • •	Mobile pho							
Address														
City State/Prov Zip/Postal code Country														
Ship a saliva kit to this patient (to submit this request, fax this completed requisition form to Invitae Client Services at 415-276-4164) Ship kit to address above Ship kit to alternate address:														
0				CLINI	CAL IN	FORMATION	D			F				
Organization name	2						Phone			Fax				
Address				City				State/	Prov	ZIP/Postal Code	Country			
				C		L TEAM								
Primary clinical o	contact (contact for general	inauires)												
Name		1		NPI	Email address (for report access)									
Ordering provide	er 🔿 Same as prima	ry clinical co	ntact											
For your convenien	ce, we have provided multip	le fields belo	w to pre-po	pulate your org	anization's	provider list. For each ord	er, indicate <u>on</u>	e ordering p	orovider.					
O Name				NPI		Email address (for report	t access)							
O Name				NPI		Email address (for report access)								
O Name				NPI		Email address (for report	t access)							
Name				NPI		Email address (for report access)								
Name				NPI		Email address (for report	t access)							
0														
	I or laboratory contacts (
	er with the primary clinical co				and manag		ae.com/signin		F 1 1	- <i>(</i>				
Name Email address (for repo				ort access)		Name			Email add	mail address (for report access)				
Name		Email addı	ess (for repo	ort access)		Name		Email add	address (for report access)					
	NCE BILLING (atta													
Attach clinical note Policyholder name	s, medical records, and/or le	tter of medi		y (LMN) to prev tionship to poli	•	We <u>do not</u> accept insuran	ce for certain t	ests <i>or</i> pati	ents outs					
,				Spouse C		Other:				Medicare insurance billing only (select one):				
Primary insurance o	company name					Primary insurance phone	e Prior-authorization #			O Patient was treated as a hospital inpatient (more than a 24 hour				
Secondary insuranc	e company name		Secondary I	member ID# Secondary insurance ph			stav) in the last 14 da				: 14 days			
					ļ		_							
PATIEN ⁻	T PAY BILLING			INSTITU	TIONA	L BILLING		PARTI	NERSH	HIP PROGRA	MS			

Invitae will send an electronic invoice to the patient email listed above. Insurance will not be billed.

Invitae will send an invoice to the organization address above. Please contact Invitae if this order should be billed to a different location.

Invitae partner code:

I	N	V	т	٨	E

Patient's first name

Patient's last name

INVITAE DIAGNOSTIC REQUISITION FORM

	SPECIN	IEN IN	IFORMATION						
Label each tube with the patient's full name, date of birt	h, and specimen collection date.	. A requisi	tion form MUST accompa	any each specime	n. www.invitae.com/specimen-requireme	nts			
Collection date (MM/DD/YYYY)	Specimen type		Specimen ID (IB # on tube):						
If not provided, date will be 1 day prior to our receipt of	O Blood O Saliva O DN DNA must be extracted in a CLIA accept blood or saliva from patien transfusion <2 weeks prior to spec	or other s ts with all	uitably certified laboratory. ogeneic bone marrow trans	. We are unable to	Is this patient deceased? Yes No Deceased date (MM/DD/YYYY)				
	REAS	ON FC	OR TESTING						
Primary indication:									
ONCOLOGY	CARDIOLOG	GY			OTHER				
Hereditary breast and ovarian cancer (HBOC) syndrome Oplyposis			Cardiomyopathy Other:		O Neurology				
Other:									
ICD-10 codes (required for insurance billing)									
PERSONAL HISTORY			FAMILY HISTORY						
Is/was this patient affected or symptomatic ¹ ? O Yes	No If yes, describe below attach clinical notes.		Is there a family history If yes, describe below a			O No			
Age at diagnosis:			Relationship to patient	Relationship to patient Maternal Diagnosed condition					
[†] Symptomatic means the patient has features or signs known o being ordered and could include findings on physical examinat	ion, laboratory tests, or imaging.					diagnosis			
Is there a hematological malignancy in this patient (curr	ent or history of)? OYes OI	No							
Has this patient had genetic testing before? OYes	No If yes, write test results attach the report.	s and							
	TE	ST SE	LECTION						
OPT	ION 1: SELECT AN IN			R TEST CATA	ALOG				
Select your c	lesired test(s) from the attac	ched test	catalog and discard a	ny pages withou	ut a selection.				
OPTION 2: INVITAE TEST CODE			OPTION 3: FAMILY F	OLLOW-UP TES	STING				
Indicate test IDs here (reference www.invitae.com/tests add-on codes will include the original panel as well as th Add-on code (optional) Test	e add-on.	n code	Invitae family follow-up testing is available at no additional charge for blood relatives of patients who receive pathogenic or likely pathogenic results (or approved VUS). Learn more at www.invitae.com/family.						
			Invitae proband F	RQ#					
	•	_	Relationship to prob	oand					
•	•		Gen	ne(s)					
OR		Variar	nt(s)						
Invitae supports customization of your test. To create a custom panel, log in to your Invitae portal account or contact Client Services. Then indicate the ID associated with that panel here.	tom panel ID		Invitae's family follow-up testing analyzes the variant(s) indicated above. If you would like this report to include any variants of uncertain significance and be eligible for re-requisition, please include billing information on this requisition form and check here:						
AUTOMATIC REFLEX: Invitae offers one re-requisition Conditions for reflex: O Regardless of initial results O Only if negative (no pathoge	U U		e same clinical area (www ex test: Test code	w.invitae.com/re-r	equisition). Preschedule it here or in your Add-on code (optional)				

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Invitae's Informed Consent for Genetic Testing (www.invitae.com/forms). For orders originating outside the US, the Patient has been informed their personal information and specimen will be transferred to and processed in the US. The Patient has been informed that Invitae may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional). If insurance billing is selected, the Patient has been informed and authorizes Invitae Corporation ("Invitae") and its designees to release information concerning testing to their insurer. The medical professional agrees to allow Invitae (1) to transfer the information from this TRF to a letter of medical necessity and/or other documentation using the medical professional's name as the signature as well as (2) assist the patient in obtaining pre-test genetic counseling from a third-party service, as required by the patient's insurance provider. I acknowledge that the Patient preceives from the insurer, the Patient has agreed to remit payment to Invitae for services rendered. I acknowledge that I offered pre-test genetic counseling to the Patient, if required by their insurer. I attest that I am authorized under applicable law to order this test.

Medical professional signature (required)	Date (MM/DD/YYYY)



Patient's last name

HEREDITARY CANCER TEST CATALOG

All tests on this form fall into a single clinical area. If your order contains tests from multiple requisition forms that include multiple clinical areas, you will need to send a specimen tube for each clinical area. Each clinical area represents an individual billable event and report. Contact Client Services with any questions. For Invitae's full test menu, visit www.invitae.com.

FREQUENTLY-ORDERED PANELS

Test code	Test name	# gene(s)	Gene list								
STAT Tur	naround Time	8- (-)									
SPECIAL INSTRUCTIONS FOR STAT PANELS: These panels have a guaranteed turnaround time of 5–12 calendar days from when the specimen is received. Genes cannot be removed and they cannot be ordered with any other non-STAT panels or genes. The option to re-requisition additional genes is available. Only blood and saliva are accepted (DNA is not accepted).											
O 50001	Invitae Breast Cancer STAT Panel	7	BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53								
	○ 50001.1 Add-on ATM gene	1	Атм								
	O 50001.2 Add-on CHEK2 gene	1	CHEK2								
O 50002	Invitae BRCA1 and BRCA2 STAT Panel	2	BRCA1, BRCA2								
Test code	Test name	# gene(s)	Gene list								
Cross-Ca	incer										
0 01101			AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1								
01102	Invitae Common Hereditary Cancers Panel Reflex to this panel Regardless of initial results Only if negative (no pathogenic/likely pathogenic results) 	47	APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, CTNNA1, DICER1, EPCAM, GREM1, HOXB13, KIT, MEN1, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PDGFRA, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP5 TSC1, TSC2, VHL								

CANCER PANELS BY ORGAN SYSTEM

Test code	Test name		# gene(s)	Gene list
Breast C	ancer			
01206	Invitae Bre	ast Cancer Guidelines-Based Panel	11	ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, TP53
	01206.1	Add-on gene with emerging data	1	BARD1
01202	02 Invitae Breast Cancer Panel O 01202.1 Add-on preliminary-evidence genes		14	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD50, STK11, TP53
			14	ABRAXAS1, AKT1, FANCC, FANCM, MRE11, MUTYH, PIK3CA, RAD51C, RAD51D, RECQL, RINT1, SDHB, SDHD, XRCC2
Breast a	nd Gyneco	logic Cancers		
01204	Invitae Bre Panel	ast and Gyn Cancers Guidelines-Based	19	ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53
	O01204.1 Add-on gene with emerging data		1	BARD1
01201	Invitae Breast and Gyn Cancers Panel		23	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53
	01201.1	Add-on preliminary-evidence genes	14	ABRAXAS1, AKT1, CDC73, FANCC, FANCM, MRE11, MUTYH, PIK3CA, POLD1, RECQL, RINT1, SDHB, SDHD, XRCC2



CANCER PANELS BY ORGAN SYSTEM (continued)

Test code	Test name		# gene(s)	Gene list
Colorect	al Cancer			
01252	Invitae Colored	tal Cancer Guidelines-Based Panel	19	APC, AXIN2, BMPR1A, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
	01252.1	Add-on gene with emerging data	1	RPS20
01251	Invitae Colored	tal Cancer Panel	20	APC, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
	01251.1	Add-on preliminary-evidence genes	10	ATM, BLM, BUB1B, CEP57, ENG, FLCN, GALNT12, MLH3, RNF43, RPS20
Addition	al Organ Sys	tems		
05313	Invitae Diamo	nd-Blackfan Anemia Panel	11	GATA1, RPL5, RPL11, RPL15, RPL26, RPL35A, RPS7, RPS10, RPS19, RPS24, RPS26
	05313.1	Add-on preliminary-evidence genes	2	RPL19, RPS29
05314	Invitae Dysker	atosis Congenita Panel	9	CTC1, DKC1, NHP2, NOP10, PARN, RTEL1, TERC, TERT, TINF2
	05314.1	Add-on preliminary-evidence genes	3	ACD, USB1, WRAP53
01271	Invitae Gastric	Cancer Panel	19	APC, BMPR1A, CDH1, CTNNA1, EPCAM, KIT, MLH1, MSH2, MSH6, NF1, PDGFRA, PMS2, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53
01302	Invitae Heredi	tary Paraganglioma-Pheochromocytoma Panel	10	MAX, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL
	01302.1	Add-on preliminary-evidence genes	4	EGLN1, FH, KIF1B, MEN1
01303	Invitae Hyperp	arathyroidism Panel	7	AP2S1, CASR, CDC73, CDKN1B, GNA11, MEN1, RET
01561	Invitae Melano	oma Panel	9	BAP1, BRCA2, CDK4, CDKN2A, MITF, POT1, PTEN, RB1, TP53
	01561.1	Add-on preliminary-evidence genes	3	BRCA1, MC1R, TERT
01411	Invitae Myeloc	ysplastic Syndrome/Leukemia Panel	16	ATM, BLM, CEBPA, EPCAM, GATA2, HRAS, MLH1, MSH2, MSH6, NBN, NF1, PMS2, RUNX1, TERC, TERT, TP53
	01411.1	Add-on preliminary-evidence genes	5	BRCA1, BRCA2, BRIP1, CHEK2, PALB2
	01411.2	01411.2 Add-on Dyskeratosis Congenita primary genes		CTC1, DKC1, NHP2, NOP10, PARN, RTEL1, TERC, TERT, TINF2
	01411.3	Add-on Fanconi Anemia genes	17	BRCA2, BRIP1, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, PALB2, RAD51C, SLX4, XRCC2
01461	Invitae Nervou	is System/Brain Cancer Panel	27	AIP, ALK, APC, DICER1, EPCAM, HRAS, LZTR1, MEN1, MLH1, MSH2, MSH6, NF1, NF2, PHOX2B, PMS2, PRKAR1A, PTCH1, PTEN, RB1, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL
	01461.1	Add-on preliminary-evidence genes	7	BAP1, BARD1, EZH2, GPC3, KIF1B, POT1, PTCH2
		Add-on Hereditary Paraganglioma- Pheochromocytoma genes	8	MAX, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127
01261	Invitae Pancre	atic Cancer Panel	20	APC, ATM, BMPR1A, BRCA1, BRCA2, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, SMAD4, STK11, TP53, TSC1, TSC2, VHL
	01261.1	Add-on preliminary-evidence genes	3	CDK4, FANCC, PALLD
	01261.2	Add-on chronic pancreatitis genes	6	CASR, CFTR, CPA1, CTRC, PRSS1, SPINK1
01362	Invitae Prostat	e Cancer Panel	12	ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PMS2, TP53
	01362.1	Add-on preliminary-evidence genes	7	ATR, BRIP1, GEN1, FANCA, PALB2, RAD51C, RAD51D



CANCER PANELS BY ORGAN SYSTEM (continued)

Test code	Test name	# gene(s)	Gene list
Addition	al Organ Systems (continued)		
01361	Invitae Renal/Urinary Tract Cancers Panel	25	BAP1, CDC73, CDKN1C, DICER1, DIS3L2, EPCAM, FH, FLCN, GPC3, MET, MLH1, MSH2, MSH6, PMS2, PTEN, REST, SDHB, SDHC, SMARCA4, SMARCB1, TP53, TSC1, TSC2, VHL, WT1
	O 01361.1 Add-on preliminary-evidence genes	7	BUB1B, CTR9, CEP57, MITF, PALB2, SDHA, SDHD
01511	Invitae Sarcoma Panel	28	APC, BLM, CDKN1C, DICER1, EPCAM, EXT1, EXT2, FH, HRAS, KIT, MLH1, MSH2, MSH6, NBN, NF1, PDGFRA, PMS2, PRKAR1A, PTCH1, RB1, RECQL4, SDHA, SDHB, SDHC, SDHD, SUFU, TP53, WRN
	O 01511.1 Add-on preliminary-evidence genes	5	CDKN2A, POT1, PTCH2, TSC1, TSC2
	O 01511.2 Add-on Diamond-Blackfan Anemia primary genes	11	GATA1, RPL11, RPL26, RPL35A, RPL5, RPL15, RPS10, RPS19, RPS24, RPS26, RPS7
01301	Invitae Thyroid Cancer Panel	7	APC, CHEK2, DICER1, PRKAR1A, PTEN, RET, TP53
	O 01301.1 Add-on preliminary-evidence genes	4	MEN1, SDHB, SDHD, WRN
Treatme	nt-Related Panel	,	
0 444743	Invitae Prostate Cancer HRR Panel	10	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, FANCL, PALB2, RAD51C, RAD51D
Pediatric	: Oncology		
01104	Invitae Pediatric Solid Tumors Panel	53	AIP, ALK, APC, AXIN2, BAP1, BLM, BMPR1A, CDC73, CDKN1C, DICER1, DIS3L2, EPCAM, EXT1, EXT2, FH, GPC3, HRAS, LZTR1, MAX, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, PRKAR1A, PTCH1, PTEN, RB1, RECQL4, REST, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1
01105	Invitae Pediatric Hematologic Malignancies Panel	16	ATM, BLM, CEBPA, EPCAM, GATA2, HRAS, MLH1, MSH2, MSH6, NBN, NF1, PMS2, RUNX1, TERC, TERT, TP53
01106	Invitae Pediatric Nervous System/Brain Tumors Panel	26	AIP, ALK, APC, DICER1, EPCAM, HRAS, LZTR1, MEN1, MLH1, MSH2, MSH6, NF1, NF2, PHOX2B, PMS2, PRKAR1A, PTCH1, PTEN, RB1, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL
	O 01106.1 Add-on Hereditary Paraganglioma- Pheochromocytoma genes	8	MAX, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127
Individu	al Hereditary Cancer Conditions		
01724	Invitae Ataxia-Telangiectasia Test	1	АТМ
01728	Invitae BAP1 Hereditary Cancer Predisposition Syndrome Test	1	ВАР1
01722	Invitae Basal Cell Nevus Syndrome Panel	2	PTCH1, SUFU
	O 01722.1 Add-on preliminary-evidence gene	1	PTCH2
01720	Invitae Birt-Hogg-Dubé Syndrome Test	1	FLCN
01730	Invitae Bloom Syndrome Test	1	BLM
01731	Invitae Carney Complex Test	1	PRKAR1A
01732	Invitae CASR-Related Conditions Test	1	CASR
01729	Invitae CDC73-Related Conditions Test	1	CDC73
01745	Invitae Chronic Pancreatitis Panel	6	CPA1, CASR, CFTR, CTRC, PRSS1, SPINK1
01703	Invitae Constitutional Mismatch Repair-Deficiency Panel	5	EPCAM, MLH1, MSH2, MSH6, PMS2
04164	Invitae Costello Syndrome Test	1	HRAS
01719	Invitae DICER1 Syndrome Test	1	DICER1
-			



CANCER PANELS BY ORGAN SYSTEM (continued)

Test code	Test name	# gene(s)	Gene list
Individua	al Hereditary Cancer Conditions (continued)		
01744	Invitae Familial Acute Myeloid Leukemia with Mutated CEBPA Test	1	СЕВРА
01709	Invitae Familial Adenomatous Polyposis Test	1	APC
01712	Invitae Familial Gastrointestinal Stromal Tumor Syndrome Panel	7	KIT, NF1, PDGFRA, SDHA, SDHB, SDHC, SDHD
01733	Invitae Familial Neuroblastoma Panel	2	ALK, PHOX2B
	O 01733.1 Add-on preliminary-evidence gene	1	KIF1B
01734	Invitae Familial Platelet Disorder with Propensity to Myeloid Malignancy Test	1	RUNX1
05311	Invitae Fanconi Anemia Panel	17	BRCA2, BRIP1, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCI, FANCH, PALB2, RAD51C, SLX4, XRCC2
05317	Invitae GATA2 Deficiency Test	1	GATA2
01701	Invitae Hereditary Breast and Ovarian Cancer Syndrome Panel	2	BRCA1, BRCA2
01707	Invitae Hereditary Diffuse Gastric Cancer Syndrome Test	1	CDH1
	O 01707.1 Add-on preliminary-evidence gene for Hereditary Diffuse Gastric Cancer Syndrome	1	CTNNA1
01727	Invitae Hereditary Leiomyomatosis and Renal Cell Cancer Test	1	FH
01723	Invitae Hereditary Papillary Renal Cell Carcinoma Test	1	MET
01711	Invitae Juvenile Polyposis Syndrome Panel	2	BMPR1A, SMAD4
01705	Invitae Li-Fraumeni Syndrome Test	1	TP53
01702	Invitae Lynch Syndrome Panel	5	EPCAM, MLH1, MSH2, MSH6, PMS2
01713	Invitae Melanoma-Pancreatic Cancer Syndrome Panel	2	CDK4, CDKN2A
01717	Invitae Multiple Endocrine Neoplasia Type 1 Test	1	MEN1
01718	Invitae Multiple Endocrine Neoplasia Type 2 Test	1	RET
01710	Invitae MUTYH-Associated Polyposis Syndrome Test	1	MUTYH
01708	Invitae Neurofibromatosis Type 1 Test	1	NF1
	O 01708.1 Add-on Legius syndrome gene	1	SPRED1
04167	Invitae Neurofibromatosis Type 2 Test	1	NF2
	O 04167.1 Add-on Schwannomatosis gene	1	SMARCB1
01725	Invitae Nijmegen Breakage Syndrome Test	1	NBN
01726	Invitae Oligodontia-Colorectal Cancer Syndrome Test	1	AXIN2
01736	Invitae Perlman Syndrome Test	1	DIS3L2
01706	Invitae Peutz-Jeghers Syndrome Test	1	STK11
01704	Invitae PTEN-Related Disorders Test	1	PTEN
01737	Invitae RECQL4-Related Disorders Test	1	RECQL4
01738	Invitae Retinoblastoma Test	1	RB1
01714	Invitae Rhabdoid Tumor Predisposition Syndrome Panel	2	SMARCA4, SMARCB1



CANCER PANELS BY ORGAN SYSTEM (continued)

Test	code	Test name							Gene list								
Indi	Individual Hereditary Cancer Conditions (continued)																
0 04	4168	Invitae S	chwan	nomatosis Pane	el			3	LZTR1	, NF2, SMARC	B1						
O 0 ⁻	1739	Invitae Simpson-Golabi-Behmel Syndrome Test						1	GPC3								
0 0.	1715	Invitae S Type Tes		ell Carcinoma o	of the C	Ovary Hypercald	emic	1	SMAR	CA4							
O 0 [.]	1721	Invitae T	uberou	ıs Sclerosis Con	nplex P	anel		2	TSC1,	TSC2							
O 0 [.]	1716	Invitae v	on Hip	pel-Lindau Sync	drome	Test		1	VHL								
O 0 ⁻	1740	Invitae W	/eaver	Syndrome Test				1	EZH2								
O 0 [.]	1741	Invitae W	/erner	Syndrome Test				1	WRN								
O 0 [.]	1742	Invitae W	/ilms T	umor Panel				6	CDC7	3, CDKN1C, DI	53L2, C	PC3, REST, WT	1				
		0174	2.1 A	dd-on prelimina	ary-evic	lence gene		1	CTR9								
0 0	1743	Invitae W	/T1-Re	lated Disorders	Test			1	WT1								
0 92	2015	Invitae Fa	amilial	Isolated Pituita	ry Adei	nomas Test		1	AIP								
HEF	REDI	TARY C	ANC	ER INDIVI	DUA	L GENES											
0	ATR		0	CDH1	0	EPCAM	0	GATA2	0	MSH3	0	PRKAR1A	0	RPL35A	0	SMARCB1	
0	ACD		0	CDK4	0	ERBB2	0	GEN1	0	MSH6	0	PRSS1	0	RPL5	0	SMARCE1	
0	AIP		0	CDKN1B	0	ERCC4	0	GNA11	0	MUTYH	0	РТСН1	0	RPS10	0	SPINK1	
0	AP2S	51	0	CDKN1C	0	EXT1	0	GPC3	0	NBN	0	PTCH2	0	RPS19	0	SPRED1	
0	ABRA	AXAS1	0	CDKN2A	0	EXT2	0	GREM1	0	NF1	0	PTEN	0	RPS20	0	STK11	
0	AKT1	1	0	СЕВРА	0	EZH2	0	HOXB13	0	NF2	0	RAD50	0	RPS24	0	SUFU	
0	ALK		0	CEP57	0	FANCA	0	HRAS	0	NHP2	0	RAD51C	0	RPS26	0	TERC	
0	APC		0	CFTR	0	FANCB	0	KIF1B	0	NOP10	0	RAD51D	0	RPS29	0	TERT	
0	ATM		0	CHEK2	0	FANCC	0	КІТ	0	NTHLI	0	RB1	0	RPS7	0	TINF2	
0	AXIN	12	0	CPA1	0	FANCD2	0	LZTR1	0	PALB2	0	RECQL	0	RTEL1	0	TMEM127	
0	BAP1	I	0	СТСІ	0	FANCE	0	MAX	0	PALLD	0	RECQL4	0	RUNX1	0	TP53	
0	BAR	01	0	CTNNA1	0	FANCF	0	MC1R	0	PARN	0	REST	0	SDHA	0	TSC1	
0	BLM		0	CTR9	0	FANCG	0	MDM2	0	PDGFRA	0	RET	0	SDHAF2	0	TSC2	
0	BMP	R1A	0	CTRC	0	FANCI	0	MEN1	0	PHOX2B	0	RINT1	0	SDHB	0	USB1	
0	BRCA	41	0	DICER1	0	FANCL	0	MET	0	PIK3CA	0	RNF43	0	SDHC	0	VHL	
0	BRCA	42	0	DIS3L2	0	FANCM	0	MITF	0	PMS2	0	RPL11	0	SDHD	0	WRAP53	
0	BRIP	1	0	DKC1	0	FH	0	MLH1	0	POLD1	0	RPL15	0	SLX4	0	WRN	
0	BUB	1B	0	EGFR	0	FLCN	0	MLH3	0	POLE	0	RPL19	0	SMAD4	0	WT1	
0	CASF	र	0	EGLN1	0	GALNT12	0	MRE11	0	ΡΟΤΊ	0	RPL26	0	SMARCA4	0	XRCC2	
0	CDC	73	0	ENG	0	GATA1	0	MSH2						ń		^	

If an order is placed using an outdated test requisition form, Invitae reserves the right to upgrade ordered tests to their current versions. View current requisition forms online at www.invitae.com/forms or consider placing your order online in the Invitae portal. Please note: Test IDs containing add-on codes will include the original panel as well as the add-on. WITHIN THE US | p: 800-436-3037 | f: 415-276-4164 | e: clientservices@invitae.com | OUTSIDE THE US | p: +1 415-930-4018 | www.invitae.com/contact | e: globalsupport@invitae.com INVITAE | 1400 16th Street, San Francisco, CA 94103, USA | www.invitae.com | © 2020 Invitae Corporation. All Rights Reserved.